These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6785 related articles for article (PubMed ID: 2511360)

  • 41. A new approach to the differential diagnosis of human malignant melanomas.
    Rougé F; Aubert C
    Cancer; 1979 Jul; 44(1):199-209. PubMed ID: 455245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
    Inoi T; Mojamdar M; Ichihashi M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1982 Sep; 92(10):1065-9. PubMed ID: 6821170
    [No Abstract]   [Full Text] [Related]  

  • 43. Acral lentiginous melanoma versus lentigo maligna melanoma among Iraqi patients.
    Sharquie KE; Al-Meshhadani SA; Al-Nuaimy AA
    Saudi Med J; 2007 Jan; 28(1):105-7. PubMed ID: 17206300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis and categorization of acral melanocytic lesions using teledermoscopy.
    Piccolo D; Soyer HP; Chimenti S; Argenziano G; Bartenjev I; Hofmann-Wellenhof R; Marchetti R; Oguchi S; Pagnanelli G; Pizzichetta MA; Saida T; Salvemini I; Tanaka M; Wolf IH; Zgavec B; Peris K
    J Telemed Telecare; 2004; 10(6):346-50. PubMed ID: 15603633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glutathionedopa in malignant melanoma.
    Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1977; 57(3):221-2. PubMed ID: 71825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Malignant melanoma of the head and neck in Scotland: an eight-year analysis of trends in prevalence, distribution and prognosis.
    Cox NH; Jones SK; MacKie RM
    Q J Med; 1987 Aug; 64(244):661-70. PubMed ID: 3444872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivo.
    Langley RG; Rajadhyaksha M; Dwyer PJ; Sober AJ; Flotte TJ; Anderson RR
    J Am Acad Dermatol; 2001 Sep; 45(3):365-76. PubMed ID: 11511832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
    Agrup G; Hafström L; Jönsson PE; Rorsman H
    Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
    [No Abstract]   [Full Text] [Related]  

  • 49. A 6 year prospective analysis of the diagnosis of malignant melanoma in a pigmented-lesion clinic: even the experts miss malignant melanomas, but not often.
    Duff CG; Melsom D; Rigby HS; Kenealy JM; Townsend PL
    Br J Plast Surg; 2001 Jun; 54(4):317-21. PubMed ID: 11355986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Precursors and early forms of malignant melanomas of the skin (author's transl)].
    Gartmann H; Pullmann H
    Z Hautkr; 1981 Apr; 56(8):509-34. PubMed ID: 7245822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A fluorescence in situ hybridization (FISH) procedure to assist in differentiating benign from malignant melanocytic lesions.
    Clemente C; Bettio D; Venci A; Scopsi L; Rao S; Ferrari A; Piris A; Mihm MC
    Pathologica; 2009 Oct; 101(5):169-74. PubMed ID: 20218056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prevention and early diagnosis of malignant melanoma].
    Selvåg E; Loeb M; Larsen TE; Thune P
    Tidsskr Nor Laegeforen; 1998 Jun; 118(15):2316-8. PubMed ID: 9691797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quick diagnosis of malignant melanoma with the touch-fluorescence method during operation.
    Morishima T; Nagashima N; Hanawa S; Fukada E; Kanematsu S; Shibata A
    Cancer; 1986 May; 57(10):2037-41. PubMed ID: 3955511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of melanin-related metabolites as markers of melanoma progression.
    Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
    Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative analysis of eumelanin and pheomelanin in human malignant-melanoma tissues.
    Morishima T; Fukuda E
    Arch Dermatol Res; 1985; 277(3):248-50. PubMed ID: 4015188
    [No Abstract]   [Full Text] [Related]  

  • 56. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 5-S-cysteinyldopa as diagnostic tumor marker for uveal malignant melanoma.
    Goto H; Usui M; Wakamatsu K; Ito S
    Jpn J Ophthalmol; 2001; 45(5):538-42. PubMed ID: 11583680
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
    Graef V; Paul E
    Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cytodiagnosis of malignant melanoma by the formaldehyde-induced fluorescence method].
    Morishima T; Shibata A; Kanematsu S; Fukada E; Hanawa S; Nagashima N
    Nihon Hifuka Gakkai Zasshi; 1985 Mar; 95(4):505-8. PubMed ID: 4021161
    [No Abstract]   [Full Text] [Related]  

  • 60. The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography.
    Hansson C; Edholm LE; Agrup G; Rorsman H; Rosengren AM; Rosengren E
    Clin Chim Acta; 1978 Sep; 88(3):419-27. PubMed ID: 699334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 340.